Pharmacokinetics in geriatric psychiatry

被引：6

作者：

Bigos K.L.

Chew M.L. ^{[1
]}

Bies R.R. ^{[2
]}

机构：

[1] Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, 3501 Terrace Street

来源：

Current Psychiatry Reports | 2008年 / 10卷 / 1期

关键词：

Risperidone; Olanzapine; Aripiprazole; Paliperidone; Rotigotine;

D O I：

10.1007/s11920-008-0007-4

中图分类号：

学科分类号：

摘要：

Safe, effective drug therapy in older adults requires an understanding of drug disposition and response in this population. Evidence suggests that physiologic changes during aging, including hepatic or renal function changes, contribute to pharmacokinetic differences. A major issue surrounding the study of older adults relates to the ability to study a large number of people in a minimally invasive way. Population pharmacokinetics provides a potential means of addressing this issue and a tool to evaluate drug exposure's magnitude and consistency. This article highlights examples of pharmacokinetic studies in psychiatry, in particular those conducted in older adults. It also reviews new drugs approved for treatment in psychiatry or neurology, many of which were developed as novel formulations (eg, extended-release transdermal film) with improved pharmacokinetic profiles or developed with regard to the actions of a specific enantiomer or metabolite. Copyright © 2008 by Current Medicine Group LLC.

引用

页码：30 / 36

页数：6

共 41 条

[1]

Mulsant B.H., Pollock B.G., Kirshner M., Et al., Serum anticholinergic activity in a community-based sample of older adults: Relationship with cognitive performance, Arch Gen Psychiatry, 60, pp. 198-203, (2003)

[2]

Gurwitz J.H., Field T.S., Harrold L.R., Et al., Incidence and preventability of adverse drug events among older persons in the ambulatory setting, JAMA, 289, pp. 1107-1116, (2005)

[3]

Mannesse C.K., Derkx F.H., de Ridder M.A., Et al., Adverse drug reactions in elderly patients as contributing factor for hospital admission: Cross sectional study, BMJ, 315, pp. 1057-1058, (1997)

[4]

Sheiner L.B., Steimer J.L., Pharmacokinetic/pharmacodynamic modeling in drug development, Annu Rev Pharmacol Toxicol, 40, pp. 67-95, (2000)

[5]

Turnheim K., When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly, Exp Gerontol, 38, pp. 843-853, (2003)

[6]

Turnheim K., Drug therapy in the elderly, Exp Gerontol, 39, pp. 1731-1738, (2004)

[7]

Ette E.I., Williams P.J., Population pharmacokinetics II: Estimation methods, Ann Pharmacother, 38, pp. 1907-1915, (2004)

[8]

Ette E.I., Williams P.J., Population pharmacokinetics I: Background, concepts, and models, Ann Pharmacother, 38, pp. 1702-1706, (2004)

[9]

Davidian M., Giltinan D.M., Nonlinear Models for Repeated Measurement Data, (1995)

[10]

Sheiner L.B., Beal S.L., Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: Routine clinical pharmacokinetic data, J Pharmacokinet Biopharm, 8, pp. 553-571, (1980)

← 1 2 3 4 5 →